Related Experiment Videos
[3 case reports of patients with malignant epilepsy treated with high doses of intravenous immunoglobulin]
Three patients with malignant epilepsia were presented. They were treated by i.v. immunoglobulin in the dose of 400 mgr/kg/bw at O, 15-day and 3-week intervals. Duration of treatment lasted 5 weeks in one child and 6 months in two children. One child had normal values of IgG2 subclass while two children showed the deficiency of this subclass. In all three children i.v. immunoglobulin therapy led to a remarkable improvement in respect both to the reduction of attacks and EEG. Due to the aggravation observed 6 months after the last dose of i.v. immunoglobulin, the therapy was repeated and led to the improvement in two children. It was pointed out in conclusion that i.v. immunoglobulin had its place in the treatment of malignant epilepsia in children.
Three patients with malignant epilepsia were presented. They were treated by i.v. immunoglobulin in the dose of 400 mgr/kg/bw at O, 15-day and 3-week intervals. Duration of treatment lasted 5 weeks in one child and 6 months in two children. One child had normal values of IgG2 subclass while two children showed the deficiency of this subclass. In all three children i.v. immunoglobulin therapy led to a remarkable improvement in respect both to the reduction of attacks and EEG. Due to the aggravation observed 6 months after the last dose of i.v. immunoglobulin, the therapy was repeated and led to the improvement in two children. It was pointed out in conclusion that i.v. immunoglobulin had its place in the treatment of malignant epilepsia in children.